Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 2, 2013, Pages 269-280

  Angelucci, Domenico ^a   Tinari, Nicola ^b   Grassadonia, Antonino ^b   Cianchetti, Ettore ^b   Ausili Cefaro, Giampiero ^b   Iezzi, Laura ^a   Zilli, Marinella ^a   Grossi, Simona ^c   Ursini, Lucia Anna ^a   Scognamiglio, Maria Teresa ^a   Castrilli, Graziella ^c   De Tursi, Michele ^b   Noccioli, Paolo ^c   Cioffi, Pasquale ^a   Iacobelli, Stefano ^b   Natoli, Clara ^b  

^a SS Annunziata Hospital   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c G Bernabeo Hospital   (Italy)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Pathological complete response; Prognostic factors; Retrospective

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; FEMALE; FOLLOW UP; HER2 POSITIVE BREAST CANCER; HORMONE RECEPTOR POSITIVE BREAST CANCER; HUMAN; LONG TERM CARE; LUMINAL A BREAST CANCER; LUMINAL B HER2 NEGATIVE BREAST CANCER; LUMINAL B HER2 POSITIVE BREAST CANCER; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NEOADJUVANT SYSTEMIC CHEMOTHERAPY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; ADJUVANT THERAPY; BREAST TUMOR; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84874984779     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1325-9     Document Type: Article

References (54)

1. Alm El-Din MA, Taghian AG (2009) Breast conservation therapy for patients with locally advanced breast cancer. Semin Radiat Oncol 19(4):229-235. doi: 10.1016/j.semradonc.2009.05.005
2. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L (2012) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9(1):16-32. doi: 10.1038/nrclinonc.2011.177
3. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21(22):4165-4174. doi: 10.1200/jco.2003.12.005
4. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24(13):2019-2027. doi: 10.1200/jco.2005.04.1665
5. Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini P, Di Cosimo S, Bruzzi P, Dowsett M, Desmedt C, Mansel RE, Olivetti L, Tondini C, Sapino A, Fenaroli P, Tortora G, Thorne H, Bertolini F, Ferrozzi F, Danova M, Tagliabue E, de Azambuja E, Makris A, Tampellini M, Dontu G, Van't Veer L, Harris AL, Fox SB, Dogliotti L, Bottini A (2011) International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr 43:147-151. doi: 10.1093/jncimonographs/lgr037
6. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN (2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13(1):228-233. doi: 10.1158/1078-0432.ccr-06-1345
7. Cameron DA, Anderson ED, Levack P, Hawkins RA, Anderson TJ, Leonard RC, Forrest AP, Chetty U (1997) Primary systemic therapy for operable breast cancer-10-year survival data after chemotherapy and hormone therapy. Br J Cancer 76(8):1099-1105
8. Cance WG, Carey LA, Calvo BF, Sartor C, Sawyer L, Moore DT, Rosenman J, Ollila DW, Graham M, 2nd (2002) Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg 236(3):295-302; discussion 302-293. doi: 10.1097/01.sla.0000027526.67560.64
9. Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Ollila DW, Klauber-DeMore N, Halle J, Sawyer L, Moore DT, Graham ML (2005) American Joint Committee on cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. JNCI J Natl Cancer Inst 97(15):1137-1142. doi: 10.1093/jnci/dji206
10. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736-750. doi: 10.1093/jnci/djp082
11. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Schechter NR, Hortobagyi GN, Buchholz TA (2004) Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 22(12):2303-2312. doi: 10.1200/jco.2004.09.062
12. Colleoni M, Bagnardi V, Rotmensz N, Gelber RD, Viale G, Pruneri G, Veronesi P, Torrisi R, Cardillo A, Montagna E, Campagnoli E, Luini A, Intra M, Galimberti V, Scarano E, Peruzzotti G, Goldhirsch A (2009) Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 116(2):359-369. doi: 10.1007/s10549-008-0223-y
13. Danforth DN Jr, Lippman ME, McDonald H, Bader J, Egan E, Lampert M, Steinberg SM, Swain SM (1990) Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer. Am Surg 56(1):6-11
14. Dawood S, Broglio K, Kau SW, Islam R, Symmans WF, Buchholz TA, McGuire SE, Meric-Bernstam F, Cristofanilli M, Hortobagyi GN, Gonzalez-Angulo AM (2008) Prognostic value of initial clinical disease stage after achieving pathological complete response. Oncologist 13(1):6-15. doi: 10.1634/theoncologist.2007-0107
15. De Placido S, De Laurentiis M, Carlomagno C, Gallo C, Perrone F, Pepe S, Ruggiero A, Marinelli A, Pagliarulo C, Panico L, Pettinato G, Petrella G, Bianco AR (2003) Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 9(3):1039-1046
16. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103(22):1656-1664. doi: 10.1093/jnci/djr393
17. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) American joint committee on cancer staging manual, 7th edn. Springer, New York
18. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12(11):1527-1532
19. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403-410
20. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15(7):2483-2493
21. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16(8):2672-2685
22. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736-1747. doi: 10.1093/annonc/mdr304
23. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23(25):5983-5992. doi: 10.1200/jco.2005.06.232
24. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G et al (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62(12):2507-2516
25. Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E (2012) Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. doi: 10.1016/j.ejca.2012.05.023
26. Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Hogel B, Darb-Esfahani S, Mehta K, Loibl S (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124(1):133-140. doi: 10.1007/s10549-010-1103-9
27. Jacquillat C, Weil M, Borel C, Auclerc G, de Maublanc MA, Housset M, Baillet F, Khayat D (1991) Tumor regression as a prognostic factor in breast cancer. Bull Cancer 78(5):435-443
28. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, von Minckwitz G (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24(12):1940-1949. doi: 10.1200/jco.2005.02.6187
29. Kaufmann M, Morrow M, von Minckwitz G, Harris JR (2010) Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel. Cancer 116(5):1184-1191. doi: 10.1002/cncr.24874
30. Kim SI, Sohn J, Koo JS, Park SH, Park HS, Park BW (2010) Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Oncology 79(5-6):324-330. doi: 10.1159/000322192
31. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17(2):460-469
32. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R (2006) Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 66(16):8266-8273. doi: 10.1158/0008-5472.can-05-4045
33. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97(3):188-194. doi: 10.1093/jnci/dji021
34. McGuire WL, Clark GM, Dressler LG, Owens MA (1986) Role of steroid hormone receptors as prognostic factors in primary breast cancer. NCI Monogr 1:19-23
35. Meyers MO, Klauber-DeMore N, Ollila DW, Amos KD, Moore DT, Drobish AA, Burrows EM, Dees EC, Carey LA (2011) Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol 18(10):2851-2857. doi: 10.1245/s10434-011-1665-8
36. Min SY, Lee SJ, Shin KH, Park IH, Jung SY, Lee KS, Ro J, Lee S, Kim SW, Kim TH, Kang HS, Cho KH (2011) Locoregional recurrence of breast cancer in patients treated with breast conservation surgery and radiotherapy following neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 81(5):e697-e705. doi: 10.1016/j.ijrobp.2010.10.014
37. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16(21):5222-5232. doi: 10.1158/1078-0432.ccr-10-1282
38. Osborne CK, McGuire WL (1979) The use of steroid hormone receptors in the treatment of human breast cancer: a review. Bull Cancer 66(3):203-209
39. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432-444. doi: 10.1016/s0140-6736(11) 61625-5
40. Pierga JY, Mouret E, Laurence V, Dieras V, Savigioni A, Beuzeboc P, Dorval T, Palangie T, Jouve M, Pouillart P (2003) Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. The role of clinical response. Eur J Cancer 39(8):1089-1096
41. Precht LM, Lowe KA, Atwood M, Beatty JD (2010) Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival. Breast J 16(4):362-368. doi: 10.1111/j.1524-4741.2010. 00935.x
42. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673-1684. doi: 10.1056/NEJMoa052122
43. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678-5685. doi: 10.1158/1078-0432.ccr-04-2421
44. Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH (2006) Primary systemic therapy of breast cancer. Oncologist 11(6):574-589. doi: 10.1634/theoncologist.11-6-574
45. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180(3):297-306
46. Schwartz GF, Birchansky CA, Komarnicky LT, Mansfield CM, Cantor RI, Biermann WA, Fellin FM, McFarlane J (1994) Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73(2):362-369
47. Semiglazov V, Eiermann W, Zambetti M, Manikhas A, Bozhok A, Lluch A, Tjulandin S, Sabadell MD, Caballero A, Valagussa P, Baselga J, Gianni L (2011) Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. Eur J Surg Oncol 37(10):856-863. doi: 10.1016/j.ejso.2011.07.003
48. Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, Russell NS, Oldenburg HS, Antonini N, Vrancken Peeters MT (2010) The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol 17(9):2411-2418. doi: 10.1245/s10434-010-1008-1
49. Tanioka M, Shimizu C, Yonemori K, Yoshimura K, Tamura K, Kouno T, Ando M, Katsumata N, Tsuda H, Kinoshita T, Fujiwara Y (2010) Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. Br J Cancer 103(3):297-302. doi: 10.1038/sj.bjc.6605769
50. Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, Camara O, Muller V, du Bois A, Kuhn T, Stickeler E, Harbeck N, Hoss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29(25):3351-3357. doi: 10.1200/jco.2010.31.4930
51. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19(22):4224-4237
52. von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kuhn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Untch M (2010) Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 28(12):2015-2023. doi: 10.1200/jco.2009.23.8303
53. von Minckwitz G, Untch M, Nuesch E, Loibl S, Kaufmann M, Kummel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Mehta K, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Muller V, Juni P (2011) Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125(1):145-156. doi: 10.1007/s10549-010-1228-x
54. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796-1804. doi: 10.1200/jco.2011.38.8595